April 17, 2025 – Talk Bio

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

2 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects

FDA clears its first prescription migraine app, from Click Therapeutics

2 months ago talkbio0Tagged click, Click Therapeutics, CT-132, first, Migraine Disorders, United States Food and Drug Administration

United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first

Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire

2 months ago talkbio0Tagged Administration occupational activities, Agencies, assumes, Budgets, HHS, Leaked, Patient Protection and Affordable Care Act, Programs - Publication Format, proposal - intent, Subsidies

Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format

RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines

2 months ago talkbio0Tagged Autistic Disorder, Environment, HHS, Kennedy, RFK gene, Vaccines

Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS

Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

2 months ago talkbio0Tagged Alarm device, Changing, Disease Outbreaks, drug safety, Icebergs, KAT5 wt Allele, Leadership, Policy, Previous, public health medicine (field), United States Food and Drug Administration, Vaccines, Visible

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

2 months ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU

2 months ago talkbio0Tagged drug price, EU, Industry, Investments, Pharma, Policy, Transplant Registry Unified Management Program, United States

EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price